Immune response in melanoma: An in-depth analysis of the primary tumor and corresponding sentinel lymph node

Modern Pathology

Volumn 25, Issue 7, 2012, Pages 1000-1010

  Ma, Michelle W ^a   Medicherla, Ratna C ^a   Qian, Meng ^a   De Miera, Eleazar Vega Saenz ^a   Friedman, Erica B ^a   Berman, Russell S ^a,b   Shapiro, Richard L ^a,b   Pavlick, Anna C ^a,b   Ott, Patrick A ^a,b   Bhardwaj, Nina ^a,b   Shao, Yongzhao ^a   Osman, Iman ^a,b   Darvishian, Farbod ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

dendritic cells; lymphatic metastases; melanoma; regulatory T cells; sentinel lymph node biopsy

Indexed keywords

CD86 ANTIGEN; GLYCOPROTEIN P 15095; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DENDRITIC CELL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGULATORY T LYMPHOCYTE; RISK; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; TUMOR RECURRENCE; TUMOR REGRESSION; UNIVARIATE ANALYSIS;

ADULT; AGED; AREA UNDER CURVE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; ROC CURVE; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84863480813     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.43     Document Type: Article

References (34)

1. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983. (Pubitemid 29109331)
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
3. Testori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol 2009;16:2018-2027.
4. Warycha MA, Zakrzewski J, Ni Q, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (r1 mm). Cancer 2009;115:869-879.
5. Kaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. Clin Pathol 2008;61:297-300. (Pubitemid 351354233)
6. Morris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008;15:316-322.
7. White Jr RL, Ayers GD, Stell VH, et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol 2011;18:3593-3600.
8. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 2006;107:2436-2445. (Pubitemid 44748527)
9. Taylor RC, Patel A, Panageas KS, et al. Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007;25:869-875. (Pubitemid 350002888)
10. Mandalà M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer 2009;45:2537-2545.
11. Chiba T, Ohtani H, Mizoi T, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004;91:1711-1717. (Pubitemid 39546145)
12. Rauser S, Langer R, Tschernitz S, et al. High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer 2010; 10:608.
13. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008;99:1704-1711.
14. French JD, Weber ZJ, Fretwell DL, et al. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010;95:2325-2333.
15. Jensen TO, Schmidt H, Møller HJ, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2011, (Epub ahead of print).
16. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-727. (Pubitemid 44453458)
17. Wich LG, Hamilton HK, Shapiro RL, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res 2009;1:35-43.
18. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 1978;42:2282-2292. (Pubitemid 9125886)
19. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002;138:603-608.
20. Gaziel-Sovran A, Segura MF, Di Micco R, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011;20:104-118.
21. Bayry J, Triebel F, Kaveri SV, et al. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+ CD25+ regulatory T cells. J Immunol 2007;178: 4184-4193. (Pubitemid 46492369)
22. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114:280-290. (Pubitemid 39071633)
23. Lee JH, Torisu-Itakara H, Cochran AJ, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11:107-112. (Pubitemid 40075784)
24. Mansfield AS, Heikkila PS, Vaara AT, et al. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 2009;9:231.
25. Mahnke K, Bedke T, Enk AH. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007; 250:1-13.
26. Lee SM, Lee YS, Choi JH, et al. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Immunol Lett 2010;132:53-60.
27. Viguier M, Lemâtre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453. (Pubitemid 38924326)
28. Schneider T, Kimpfler S, Warth A, et al. Foxp3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 2011;6: 432-438.
29. Mansfield AS, Holtan SG, Grotz TE, et al. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol 2011;24: 487-494.
30. Ebert LM, Tan BS, Browning J, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 2008;68:3001-3009. (Pubitemid 351556301)
31. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009;106:20429-20434.
32. Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 2003;8:451-458. (Pubitemid 37238873)
33. Navarrete AM, Delignat S, Teillaud JL, et al. CD4+ CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells. Vaccine 2011;29: 2649-2652.
34. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.